What is the recommended dosing regimen of pazopanib (generic) for adult patients with renal cell carcinoma, including dose reductions for toxicity and adjustments for hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Dosing of Pazopanib in Renal Cell Carcinoma

The standard recommended dose of pazopanib for renal cell carcinoma is 800 mg orally once daily, taken on an empty stomach (at least 1 hour before or 2 hours after a meal), with tablets swallowed whole and not crushed. 1

Standard Dosing Regimen

The FDA-approved dosing is:

  • 800 mg once daily (four 200 mg tablets)
  • Timing: Without food—at least 1 hour before or 2 hours after meals
  • Administration: Swallow tablets whole; do not crush (crushing increases absorption rate and systemic exposure)
  • Duration: Continue until disease progression or unacceptable toxicity 1

If a dose is missed, do not take it if less than 12 hours remain until the next scheduled dose 1.

Dose Reductions for Toxicity

For renal cell carcinoma specifically, a structured two-step dose reduction algorithm applies:

First dose reduction: 400 mg once daily

Second dose reduction: 200 mg once daily

Permanently discontinue if unable to tolerate 200 mg once daily 1

Specific Toxicity-Based Modifications

Hepatotoxicity (the most critical concern with a black box warning):

  • ALT 3-8× ULN (isolated): Continue treatment, monitor liver function weekly until return to Grade 1 or baseline
  • ALT >8× ULN (isolated): Withhold until improvement to Grade 1/baseline; if resuming, use maximum 400 mg once daily with weekly liver monitoring for 8 weeks
  • ALT >3× ULN + bilirubin >2× ULN: Permanently discontinue 1

Hypertension (Grade 2-3):

  • Reduce dose per Table 1 (first to 400 mg, then to 200 mg if needed)
  • Initiate or adjust antihypertensive therapy
  • Permanently discontinue if Grade 3 persists despite dose reductions and antihypertensive management 1

Hemorrhagic events:

  • Grade 2: Withhold until ≤Grade 1, resume at reduced dose; permanently discontinue if Grade 2 recurs
  • Grade 3-4: Permanently discontinue 1

Hepatic Impairment Adjustments

Mild hepatic impairment: 800 mg once daily (standard dose) is well tolerated 2

Moderate hepatic impairment: Reduce to 200 mg once daily 2

Severe hepatic impairment: Reduce to 200 mg once daily, though pazopanib is generally not recommended in this population due to safety concerns 3, 2

The lower tolerated doses in moderate-to-severe hepatic impairment are not due to decreased drug clearance but rather to increased toxicity sensitivity 2.

Therapeutic Drug Monitoring Considerations

While not standard practice, emerging evidence supports therapeutic drug monitoring (TDM) for pazopanib optimization:

Target trough concentration (Cmin): ≥20.5 mg/L for efficacy in RCC 4

Upper toxicity threshold: Cmin >34 mg/L associated with 3.35-fold increased liver toxicity risk 5

Optimal therapeutic window: 20-34 mg/L 5

A prospective study demonstrated that Cmin-guided dosing (targeting 20 mg/L) led to individualized doses ranging from 400-1,800 mg daily, with successful dose escalations in patients with subtherapeutic levels 4. This approach is classified as "viable" for TDM implementation, though not yet standard of care 4.

Clinical Context and Pitfalls

Common pitfall: Approximately 60% of patients require dose reductions due to toxicity in real-world practice, with severe liver toxicity necessitating treatment interruptions in over 10% of cases 5. This high rate of dose modification underscores the importance of close monitoring, particularly during the first 8 weeks of therapy.

Food effect: Taking pazopanib with food significantly increases systemic exposure and toxicity risk. The fasted state requirement is critical and non-negotiable 1.

Recent optimization data: Model-informed dosing suggests that initiating treatment at 600 mg once daily (fasted) may reduce liver toxicity risk while maintaining adequate Cmin ≥20.5 mg/L in 76% of patients 5. However, this is not yet incorporated into FDA labeling, and the standard 800 mg dose remains the official recommendation.

Drug interactions: Dose adjustments are required with strong CYP3A4 inhibitors (reduce to 200 mg once daily or 100 mg twice daily) 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.